Compare GSK plc (GSK) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nomura Holdings Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Nomura Holdings Inc trades at $9.85 (market cap $29.38B). The key difference: GSK plc is far larger — about 3.4× Nomura Holdings Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NMR | |
|---|---|---|
Market Cap | $101.34B | $29.38B |
Sector | Health | Financials |
52-Week High | $61.18 | $10.04 |
52-Week Low | $36.20 | $6.30 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Nomura Holdings (NMR) trades at $9.85, up 1.03% with a bullish technical outlook from moving averages. The stock shows strong fundamentals with a P/E of 13.65, net income margin of 19.66%, and record annual profit in 2025. Recent news highlights expansion in wholesale revenue and strategic acquisitions, including a U.S. fund management push and digital asset subsidiary progress.
Outlook is positive due to valuation discounts versus peers and ROE expansion potential, but risks include earnings misses in recent quarters and rising debt-to-asset ratios. Analysts are mixed with 33% buy ratings, suggesting cautious optimism amid integration costs from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
